肝脏铁积累在补偿威尔逊病的化疗法:儿童的前性评估
Nitu Kumari1, Moinak S Sarma1, Asmita Arya2
1Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh 226014, India.
Journal of clinical and experimental hepatology
|March 5, 2026
概括
威尔逊病 (WD) 患者经常表现出严重的肝脏铁过载,特别是那些接受长期化疗法的患者. 建议使用磁共振成像 (MRI) 来选WD中的铁积累.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 医学生物化学 医学生物化学
- 放射学 放射学是一门学科.
背景情况:
- 威尔逊病 (WD) 的特点是铜分泌受损,导致其在肝脏等器官中积累.
- 铁氧化酶Ceruloplasmin在铁代谢中发挥作用,这表明WD与铁过载增加之间存在潜在的联系.
研究的目的:
- 评估威尔逊病患者肝脏铁过载的患病率和特征.
- 评估与对照组相比,WD患者的铁代谢生物标志物和肝脏铁度 (LIC).
主要方法:
- 招募了补偿和补偿的WD患者,化时间≥3年,血清可交换铜含量低 (ExCu <1.15μmol/L).
- 评估了铁代谢生物标志物,并进行了T2权重的肝磁共振成像 (MRI) 来确定LIC.
- 定义的高LIC是干重量 (dw) >1.5 mg/g.
主要成果:
- 49%的WD患者的LIC高,与10%的对照组相比 (P = 0.027).
- 经过≥6年的化疗的患者显示,高LIC的患病率 (89%) 与<6年 (58%) (P = 0.03) 的患者相比较高.
- 较长的化持续时间与血清铁氧化酶活性相反相关,而血清费里丁与LIC的相关性较差. 低的ExCu与高的LIC相关.
结论:
- 大约一半的WD患者经历了严重的肝脏铁过载,特别是长期化疗法和低ExCu.
- 肝脏MRI是一种推的查工具,用于检测威尔逊病的铁过载.
- 需要进一步研究WD中铜和铁代谢的相互作用.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
244
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
304
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
304
Esophageal Varices-II: Clinical Features and Management
697
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
697
Diseases of the Liver and Gallbladder
2.2K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
Extraction: Advanced Methods
1.2K
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
1.2K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
318
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
318


